Keystone EC: Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol. 2003, 15: 253-258. 10.1097/00002281-200305000-00012.
Article
CAS
PubMed
Google Scholar
Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, et al: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46: 1470-1479. 10.1002/art.10294.
Article
CAS
PubMed
Google Scholar
Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349: 1907-1915. 10.1056/NEJMoa035075.
Article
CAS
PubMed
Google Scholar
Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991, 147: 2461-2466.
CAS
PubMed
Google Scholar
Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001, 19: 225-252. 10.1146/annurev.immunol.19.1.225.
Article
CAS
PubMed
Google Scholar
Verwilghen J, Lovis R, De Boer M, Linsley PS, Haines GK, Koch AE, Pope RM: Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol. 1994, 153: 1378-1385.
CAS
PubMed
Google Scholar
Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA: CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 1996, 184: 783-788. 10.1084/jem.184.2.783.
Article
CAS
PubMed
Google Scholar
Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996, 183: 2541-2550. 10.1084/jem.183.6.2541.
Article
CAS
PubMed
Google Scholar
Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA: Cutting Edge: CD28 controls peripheral homeostasis of CD4+, CD25+ Regulatory T cells. J Immunol. 2003, 171: 3348-3352.
Article
CAS
PubMed
Google Scholar
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991, 174: 561-569. 10.1084/jem.174.3.561.
Article
CAS
PubMed
Google Scholar
Walunas TL, Bluestone JA: CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol. 1998, 160: 3855-3860.
CAS
PubMed
Google Scholar
Finck BK, Linsley PS, Wofsy D: Treatment of murine lupus with CTLA4Ig. Science. 1994, 265: 1225-1227.
Article
CAS
PubMed
Google Scholar
Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK: Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol. 1995, 154: 1481-1490.
CAS
PubMed
Google Scholar
Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 1995, 95: 2783-2789.
Article
PubMed Central
CAS
PubMed
Google Scholar
Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD: A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol. 2000, 164: 136-143.
Article
CAS
PubMed
Google Scholar
Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ: Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995, 96: 987-993.
Article
PubMed Central
CAS
PubMed
Google Scholar
Daikh DI, Wofsy D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001, 166: 2913-2916.
Article
CAS
PubMed
Google Scholar
Tada Y, Nagasawa K, Ho A, Morito F, Ushiyama O, Suzuki N, Ohta H, Mak TW: CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol. 1999, 162: 203-208.
CAS
PubMed
Google Scholar
Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, Gawronska-Szklarz B: The expansion of CD4+ CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther. 2003, 5: R210-R213. 10.1186/ar766.
Article
PubMed Central
CAS
PubMed
Google Scholar
Weinblatt M, Schiff M, Goldman M, Kremer J, Breazna A, Becker JC: A pilot, multi-center, randomized, double-blind, placebo controlled [study] of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum. 2002, S204-Suppl
Emery P, Russell A, Kremer J, Williams GR, Li T, Nuamah I, Becker JC, Weisman MH: Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a selective co-stimulation modulator, over one year in patients with active rheumatoid arthritis using methotrexate [abstract]. Arthritis Rheum. 2003, S4-Suppl
Emery P, Westhovens R, Moreland L, Nuamah I, Aranda R, Becker J, Kremer J: CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methotrexate showed correlation between the clinical response and key biomarkers [abstract]. Presented at: European League Against Rheumatism Annual Meeting, Lisbon, Portugal. 2003, [http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2003SCIE-abstract&TEMPLATE=&keyf=0896&showHide=show&client=]
Google Scholar
Kremer J, Shergy W, Tindall E, Aranda R, Nuamah I, Zhou Y, Becker JC: Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S182-Suppl
Dougados M, Weswthovens R, St Clair EW, Aranda R, Nuamah I, Zhou Y, Vratsanos G, Becker JC: Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S185-Suppl
Moreland L, Weisman M, Alten R, Aranda R, Zhou Y, Wu K, Nuamah I, Becker JC: Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years [abstract]. Arthritis Rheum. 2004, S563-Suppl
Kremer J, Westhovens R, Moreland L, Emery P, Russell A, Ge Z, Aranda R, Becker JC: Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in INadequate responders to Methotrexate) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX. 2004, [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={85C06A69-418B-47A1-BEF0-F919C8C4F640}&MKey={6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey={AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey={8FF4FA39-962F-41CF-B617-5E132EB117E5}]
Google Scholar
Genovese MC, Luggen M, Schiff M, Sherrer Y, Nuamah I, Aranda R, Becker JC, Dougados M: Efficacy and safety of abatacept (CTLA4Ig), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-a[ED:alpha] therapy: results of the phase III ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate responders) trial [abstract]. Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX. 2004, [http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={460C7526-77D4-4A49-AD2D-440A2515EE22}&MKey={6A95EDC3-27BB-49C8-9CE4-3C06FC50D63E}&AKey={AA45DD66-F113-4CDD-8E62-01A05F613C0D}&SKey={100FBD25-6760-48B9-A4F5-EEEE63E1DAAA}]
Google Scholar